

Article

Carboxylated Acyclonucleosides: Synthesis and RNase A Inhibition

Kaustav Chakraborty, Swagata Dasgupta * and Tanmaya Pathak *

Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India;
E-Mail: kaustav@chem.iitkgp.ernet.in

* Authors to whom correspondence should be addressed;
E-Mails: swagata@chem.iitkgp.ernet.in (S.D.); tpathak@chem.iitkgp.ernet.in (T.P.);
Tel.: +91-3222-283-306 (S.D.); +91-3222-283-342 (T.P.).

Academic Editor: Mahesh Lakshman

Received: 17 December 2014 / Accepted: 20 March 2015 / Published: 3 April 2015

Abstract: Strategically designed carboxylated acyclonucleosides have been probed as a new class of RNase A inhibitors. Several experimental and theoretical studies have been performed to compile relevant qualitative and quantitative information regarding the nature and extent of inhibition. The inhibition constant (K_i) values were determined using a UV-based kinetics experiment. The changes in the secondary structure of the enzyme upon binding with the inhibitors were obtained from circular dichroism studies. The binding constants for enzyme-inhibitor interactions were determined with the help of fluorescence spectroscopy. Docking studies were performed to reveal the possible binding sites of the inhibitors within the enzyme. The cytosine analogues were found to possess better inhibitory properties in comparison to the corresponding uracil derivatives. An increment in the number of carboxylic acid groups (-COOH) in the inhibitor backbone was found to result in better inhibition.

Keywords: acyclonucleosides; RNase A; inhibition; kinetics; docking

1. Introduction

Ribonucleases are a family of digestive enzymes that degrade RNA [1]. Effective inhibition of their enzymatic activity has become a topic of growing interest with the realization that the detrimental biological activities manifested by certain members of this family [2–6] are critically dependent upon

their ribonucleolytic activity [7,8]. Ribonuclease A (RNase A) is a representative member of this family [9,10] that works at the juncture of the transcription and translation processes, thereby maintaining the cellular RNA levels. Structural homology among the various members of this family [11–13] permits the use of Ribonuclease A (RNase A) as a model system to explore structure–activity relationships.

Recent reports from our laboratory have revealed that modified nucleoside carboxylic acids manifest RNase A inhibitory properties in a competitive, reversible manner [14–21]. These molecules have an added advantage over the reported phosphate- or pyrophosphate-based nucleotide inhibitors [22–31] as the polyionic nature of the latter hampers their migration through the cell membrane [32]. The active site of RNase A consists of several subsites made up of polar amino acid residues for specific recognition [9,33] (Figure 1). The cleavage of the phosphodiester bond of RNA at the P₁ subsite involves the two His residues (His 12 and His 119) participating in a conjugate acid-base mechanism [34,35]. At physiological pH, the carboxylic acid (-COOH) group(s) in the inhibitor remains deprotonated, and interacts electrostatically with the protonated His and Lys residues present at the ribonucleolytic site [36]. This perturbation of the protonating/deprotonating environment of the P₁ subsite results in the inhibition of RNase A.

Following the same hypothesis, it was expected that carboxylated acyclonucleosides may elicit similar inhibitory properties because of their in-built structural features. The absence of the rigid ribose ring further enhances the flexibility of these molecules, and generates additional information on the importance of the furanoside ring. We report the synthesis of several uracil- and cytosine-based modified acyclonucleosides followed by the exploration of their RNase A inhibitory properties. The nucleobases have been carefully selected, as the B₁ subsite of RNase A shows preferential recognition towards pyrimidine bases. The acidity of the molecules has been increased via stepwise incorporation of carboxylic acid groups in the molecular framework to study the resulting effect on their inhibition capacities.





Figure 1. Key residues of the active site of RNase A.

2. Results and Discussion

2.1. Synthesis of Nucleosides


The uracil-glycine conjugate **3** was synthesized according to a literature reported procedure [37] (Scheme 1). Syntheses of other modified uracil derivatives were achieved via coupling of the known uracil-1-acetic acid **1** [37] with suitable secondary amines, followed by hydrolysis and/or deprotection as required (Scheme 1). The synthesis of the uracil-diethanolamine conjugate **5** [38] was achieved by coupling **1** with the *tert*-butyldimethyl silyl (TBDMS)-protected diethanolamine, and deprotecting the TBDMS groups of the coupled product **4** with a catalytic amount of CH_3COCl in methanol (Scheme 1). TBDMS-protected *N*-(2-hydroxyethyl)glycine ethyl ester, on EDC-HOBT-mediated coupling with **1**, generated compound **6**. Deprotection of the TBDMS group produced compound **7**, which was converted to the corresponding acid **8** via hydrolysis (Scheme 1). Again, **1** was coupled with diethyl iminodiacetate to afford the corresponding diester **9**. The diacid derivative **10** was produced from **9** by base-mediated hydrolysis (Scheme 1).



Scheme 1. Synthesis of uracil-based modified acyclonucleosides.

Syntheses of the corresponding cytosine-based molecules were achieved using the reported cytosine derivative **11** [39] as the starting material (Scheme 2). EDC-HOBT-mediated coupling of glycine ethyl

ester to compound **11** produced the coupled product **12**. The deprotection of the *tert*butyloxy carbonyl (BOC) groups of **12** by TFA resulted in the formation of compound **13**. The hydrolysis of the ester group provided the desired acid derivative **14** (Scheme 2). Compound **11**, on coupling with TBDMS-protected diethanolamine, generated the coupled derivative **15**. TFA treatment of compound **15** afforded the deprotected cytosine-diethanolamine conjugate **16** (Scheme 2). Again, coupling of the TBDMS-protected N-(2-hydroxyethyl)glycine ethyl ester with compound **11**, followed by hydrolysis and deprotection of the resulting ester **17**, afforded the corresponding hydroxy acid derivative **18** (Scheme 2). Finally, the diacid **21** was obtained from compound **11** following a similar sequence of steps (Scheme 2). Compound **11**, on coupling with diethyl iminodiacetate, produced the coupled product **19**. Compound **19** was transformed to compound **20** by treatment with TFA. Base-mediated hydrolysis of **20** afforded the desired diacid derivative **21**.



Scheme 2. Synthesis of cytosine-based modified acyclonucleosides.

2.2. RNase A Inhibition

Qualitative indication of RNase A inhibition by the synthetic inhibitors was obtained from a comparative agarose gel-based assay by monitoring the degradation of RNA by RNase A (Figures 2 and 3). The most intense band observed in lane I in each gel is due to the presence of only RNA. The faint band in lane II is due to the maximum possible degradation of RNA by RNase A. Different intensities of bands from lane III to VI revealed different extents of inhibition by the inhibitors at a fixed concentration (0.5 mM). The histograms obtained by plotting the relative intensities of the bands revealed that compounds **U-ol-acid (8)**, **C-ol-acid (18)**, **U-di-acid (10)**, and **C-di-acid (21)** were relatively more potent inhibitors in comparison to the others. These experimental observations reaffirmed our assumption that increasing the acidity of the molecules leads to an increase in the inhibitory property of the inhibitor.




Figure 2. Agarose gel-based assay for RNase A (1 μ M) Inhibition. (A) lane I: RNA (10 mg/mL), lane II: RNA + RNase A, lanes III, IV, V, VI: RNA + RNase A + **U-ol-ol (5)**, **U-acid (3)**, **U-ol-acid (8)**, and **U-di-acid (10)** (0.5 mmol), respectively. (B) Histogram showing the relative band intensities of agarose gel assay (the data are the mean \pm SD).




Figure 3. Agarose gel-based assay for RNase A (1 μ M) Inhibition. (A) lane I: RNA (10 mg/mL), lane II: RNA + RNase A, lanes III, IV, V, VI: RNA + RNase A + **C-ol-ol (16)**, **C-ol-acid (18)**, **C-di-acid (21)**, and **C-acid (14)** (0.5 mmol), respectively. (B) Histogram showing the relative band intensities of agarose gel assay (the data are the mean \pm SD).

In order to determine the type of inhibition and the inhibition constant (K_i) values, kinetic experiments were performed with compounds **U-ol-acid (8)**, **U-di-acid (10)**, **C-ol-acid (18)**, and **C-di-acid (21)**. The inhibition constant values are given in Table 1. The competitive nature of inhibition in all the cases was apparent from the nature of the Lineweaver–Burk plots obtained from the kinetic experiments (Figure 4 and Figure S1 (SI)). The numerical order of the inhibition constant (K_i) values indicated that **U-di-acid (10)** and **C-di-acid (21)** are the two most potent inhibitors of the series. The results are in good agreement with the results obtained from agarose gel-based assay, suggesting a correlation of inhibitory efficiency with the number of carboxylic acid groups present in the concerned inhibitor. The cytosine analogue **C-di-acid (21)** was found to possess superior inhibitory property in comparison to the corresponding uracil derivative **U-di-acid (10)**.

Table 1. Inhibition constants (K_i) of the inhibitors.

Inhibitor	K_i * (μM)
U-ol-acid (8)	454 ± 9
C-ol-acid (18)	356 ± 7
U-di-acid (10)	301 ± 15
C-di-acid (21)	235 ± 9

* The data are the mean \pm SD.




Figure 4. Lineweaver–Burk plot for inhibition of RNase A by **C-di-acid (21)** of 0.15 (▲), 0.05 (■), or 0 (●) mM, with 2',3'-cCMP concentrations of 0.75–0.52 mM and RNase A concentration of 9.8 μM .

Inhibitors of RNase A are known to perturb the secondary structure of the enzyme upon binding [40–44]. A model drug–protein interaction study showed that 3'-azido-3'-deoxythymidine increases the α -helix content of RNase A [40]. Similar increments were observed with 3'-*O*-carboxy esters of thymidine, which inhibited RNase A in reversible competitive mode [42]. Therefore, the probable changes in the secondary structure of the enzyme by the inhibitors were monitored by observing the CD spectra of RNase A in the absence or presence of compounds **U-di-acid (10)** and **C-di-acid (21)** (Figure 5). Both the inhibitors induced moderate changes in the secondary structure of the enzyme, which was reflected in the enhanced α -helix content. The α -helix content in native RNase A

was 22.7%, which was found to increase upon binding with **U-di-acid (10)** and **C-di-acid (21)** to 24.7% and 29.2%, respectively.




Figure 5. CD spectra of RNase A in absence or presence of **U-di-acid (10)** and **C-di-acid (21)**.

The fluorescence emission intensity of RNase A due to the presence of six Tyr residues is found to decrease upon interactions with small molecule inhibitors [40–44]. The emission spectrum of RNase A in presence of **U-di-acid (2.10)** and **C-di-acid (2.21)** at 25 °C showed quenching of the fluorescence intensity of Tyr residues (Figure S2, (SI)). The fluorescence quenching study was used to calculate the binding parameters for enzyme-inhibitor interactions. Binding constants (K_b) calculated from the experiment were found to be in the order of 10^5 for **C-di-acid (21)** and 10^4 for **U-di-acid (10)** (Table S1, (SI)), indicating strong binding of the inhibitors with the enzyme.

To gain an insight into the probable binding sites, protein-ligand docking studies were undertaken. The docked conformations shown in Figure 6 revealed that the nucleobase-amino acid conjugates were in close proximity to the amino acid residues of the P₁ subsite, resulting in a competitive mode of inhibition, as observed from the kinetic study. The carboxylic acid (-COOH) groups, in each case, were positioned close to His12 and His 119, probably engaged in hydrogen bonding with the residues. For the cytosine-based inhibitors, the N3 and -NH₂ groups of the nucleobase were near to several amino acid residues (Arg39, Lys41, Val43), thus increasing the possibility of polar interactions between them. Such interactions were absent for the uracil-derived inhibitors. These extra interactions probably contribute to the experimentally observed better inhibitory potency of the cytosine inhibitors. Apart from the interactions with the active site residues, one of the carboxylic acid (-COOH) groups of **U-di-acid (10)** was found to be within hydrogen bonding distance of Oε1 of Gln11. Similarly, one -COOH group of **C-di-acid (21)** was engaged in hydrogen bonding with Phe120. Such favorable interactions of the -COOH groups may possibly result in the better inhibition capacity of the inhibitors. The docked enzyme-inhibitor complexes also revealed that the nucleobase in the acyclic structure is not in close proximity to the amino acid residues of the pyrimidine binding subsite B₁ (Thr45, Asp83, Phe120). It can, therefore, be assumed that the ribose ring in the nucleosides may have a role in recognition of the inhibitors by the enzyme. A detailed account of all the interactions between the inhibitors and the enzyme has been provided in Table S2 (SI).

A further clarification regarding the possible binding sites of the inhibitors was obtained by calculating the changes in accessible surface area (ΔASA) of the interacting residues between the free and complexed forms of the enzyme (Table 2). The measurements revealed that the accessible surface area of the amino acid residues of the P₁ subsite (His12, His 119 and Lys 41) was largely affected upon binding with the inhibitors. The observed results correlate well with the results of the docking study, suggesting that the inhibitors do bind to the P₁ subsite of RNase A.




Figure 6. Docked poses of (A) C-di-acid (21) (yellow) and U-di-acid (10) (red), and (B) U-ol-acid (8) (green) and C-ol-acid (18) (brown) with RNase A (1FS3).

Table 2. Changes in accessible surface area (ΔASA) of the interacting residues between the uncomplexed and complexed forms of RNase A.

Amino Acid Residue	ASA (\AA^2) in RNase A	ΔASA (\AA^2) for Different Inhibitors			
		U-ol-Acid (8)	C-ol-Acid (18)	U-di-Acid (10)	C-di-Acid (21)
Lys 7	88.03	42.88	41.75	29.62	43.82
His 12	12.64	7.09	7.76	9.21	7.53
Arg 39	142.03	25.81	29.72	5.06	30.79
Lys 41	36.39	26.80	31.58	33.00	31.31
His 119	85.05	33.62	28.29	26.69	26.64

3. Experimental Section

3.1. General Methods

All reagents and fine chemicals were purchased from commercial suppliers and were used without further purification. Column chromatography was performed with silica gel (230–400 mesh). Solvents were dried and distilled following standard methods. TLC was carried out on precoated plates (Merck silica gel 60, f_{254}). ^1H and ^{13}C -NMR for the compounds were recorded at 200 and 50 MHz, respectively, using a Bruker NMR instrument. For ^1H and ^{13}C -NMR spectra in D_2O , CH_3CN was used as internal standard. Chemical shifts are reported in parts per million (ppm, δ scale). Methylene carbons have been identified using DEPT spectrum. Melting points were determined in open-end capillary tubes. Bovine pancreatic RNase A, RNA (*Torula utilis*), and 2',3'-cCMP were purchased

from commercial suppliers. UV-vis measurements were made using a UV-vis spectrophotometer (Shimadzu 2450). Concentrations of the solutions were estimated spectrophotometrically using the following data: $\epsilon_{278.5} = 9800 \text{ M}^{-1} \cdot \text{cm}^{-1}$ (RNase A) [45] and $\epsilon_{268} = 8500 \text{ M}^{-1} \cdot \text{cm}^{-1}$ (2',3'-cCMP) [22]. CD measurements were carried out on a Jasco-810 automatic recording spectrophotometer. Fluorescence measurements were carried out using a Horiba Jobin Yvon Fluoromax-4 Spectrofluorimeter.

3.2. General Procedure for Carboxylic Acid–Amine Coupling Reaction

To a well-stirred solution of carboxylic acid (**1**, **11**) (1 mmol) in DMF (5 mL) at 0 °C was added EDC-HCl (1.2 mmol) followed by triethylamine (1.2 mmol) and the stirring was further continued at this temperature. After 10 min, HOBT (1.2 mmol) was added and the reaction mixture was allowed to warm back to room temperature. Amine (1 mmol) was added to the resulting solution and the stirring was allowed to continue overnight. The reaction mixture was then poured into a brine solution (50 mL) and extracted with EtOAc (3 × 20 mL). Organic extracts were pooled together, dried over anhydrous Na₂SO₄, filtered, and the filtrate was evaporated under reduced pressure. The resulting residue was purified by column chromatography over silica gel (EtOAc/petroleum ether) to obtain pure coupling products (**4**, **6**, **9**, **12**, **15**, **17**, **19**).

3.3. General Procedure for Deprotection of –TBDMS Group

To a well-stirred solution of compound (**4**, **6**) (1 mmol) in methanol (10 mL), was added CH₃COCl (cat). The resulting solution was allowed to stir for 2 h at room temperature. The solvent was evaporated under reduced pressure and the resulting residue was purified by column chromatography over silica gel (DCM/MeOH) to obtain pure products (**5**, **7**).

3.4. General Procedure for the Deprotection of –BOC Group/Simultaneous Deprotection of –BOC Group and –TBDMS Group

The compound (**12**, **15**, **19**) (1 mmol) was dissolved in 1:1 TFA/DCM (5 mL) and the resulting solution was stirred at room temperature for 4 h. The solvent was evaporated under reduced pressure and the resulting residue was purified by column chromatography over silica gel (DCM/MeOH) to obtain pure products (**13**, **16**, **20**).

3.5. General Procedure for Ester Hydrolysis

To a well-stirred solution of the compound (**7**, **9**, **13**, **20**) (1 mmol) in methanol (5 mL) at 0 °C was added 1 N NaOH solution (2 mL) dropwise. The resulting solution was allowed to warm back up to room temperature and stirred for 1 h. After evaporation of methanol under reduced pressure, the resulting residue was dissolved in water (10 mL) and neutralized with acidic amberlyte. The resulting mixture was filtered, and the filtrate was evaporated under reduced pressure. The resulting residue was purified by column chromatography over silica gel (DCM/MeOH) to obtain pure products (**8**, **10**, **14**, **21**).

N,N-Bis-[2-(*tert*-butyldimethylsilyloxy)-ethyl]-2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetamide (**4**): Compound **1** (0.68 g, 3.99 mmol) was converted to compound **4** (1.28 g, 66%) following the general

procedure in Section 3.2. $R_f = 0.4$ [30% EtOAc in pet ether]. White solid. M.P: 122–124 °C. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 0.02 (s, 6H), 0.06 (s, 6H), 0.86 (s, 9H), 0.88 (s, 9H), 3.47 (t, $J = 5.5$ Hz, 2H), 3.59 (t, $J = 5.1$ Hz, 2H), 3.71–3.80 (m, 4H), 4.66 (s, 2H), 5.69 (d, $J = 8.0$ Hz, 1H), 7.11 (d, $J = 7.8$ Hz, 1H), 9.28 (bs, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ -5.3, -5.2, 18.3, 18.5, 26.0, 26.1, 48.1 (CH_2), 49.2 (CH_2), 51.1 (CH_2), 61.0(CH_2), 61.5 (CH_2), 102.1, 145.4, 151.2, 163.9, 167.0. HRMS (ESI $^+$): m/z calcd for $\text{C}_{22}\text{H}_{44}\text{N}_3\text{O}_5\text{Si}_2$ ($\text{M}+\text{H}$) $^+$: 486.2820; found: 486.2827.

2-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-N,N-bis-(2-hydroxy-ethyl) acetamide (5): Compound **5** [38] (0.39 g, 81%) was obtained from compound **4** (0.9 g, 1.85 mmol) following the general procedure in Section 3.3. White solid. $R_f = 0.4$ [15% MeOH in DCM]. $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 3.31–3.58 (m, 8H), 4.67 (s, 2H), 4.75–4.80 (m, 1H), 5.01–5.05 (m, 1H), 5.54 (d, $J = 7.8$ Hz, 1H), 7.47 (d, $J = 7.8$ Hz, 1H), 11.23 (bs, 1H).

{[2-(tert-Butyldimethylsilyloxy) ethyl]-[2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl-acetyl)] amino}acetic acid ethyl ester (6): Compound **1** (0.93 g, 5.47 mmol) was converted to compound **6** (1.40 g, 62%) following the general procedure in Section 3.2. $R_f = 0.3$ [40% EtOAc in pet ether]. White solid. M.P: 171–172 °C. The compound was obtained as a mixture of rotamers as indicated by the NMR spectra. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 0.01 (s, 6H), 0.06 (s, 6H), 0.86 (s, 9H), 0.87 (s, 9H), 1.20–1.32 (m, 3H), 3.52–3.56 (m, 2H), 3.70–3.81 (m, 2H), 4.10–4.24 (m, 4H), 4.30 (s, 2H), 4.46 (s, 2H), 4.71 (s, 2H), 5.68–5.73 (m, 1H), 7.13–7.26 (m, 1H), 9.39 (bs, 1H), 9.51 (bs, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ -5.3, 14.3, 18.4, 26.0, 26.1, 47.9 (CH_2), 48.6 (CH_2), 50.8 (CH_2), 61.4 (CH_2), 61.6 (CH_2), 62.2 (CH_2), 102.3, 145.4, 151.1, 163.9, 167.5, 168.9, 172.9. HRMS (ESI $^+$): m/z calcd for $\text{C}_{18}\text{H}_{32}\text{N}_3\text{O}_6\text{Si}$ ($\text{M}+\text{H}$) $^+$: 414.2060; found: 414.2088.

[[2-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl-acetyl)-(2-hydroxyethyl)-amino] acetic acid ethyl ester (7): Compound **7** (0.48 g, 55%) was generated from compound **6** (1.21 g, 2.90 mmol) following the general procedure in Section 3.3. $R_f = 0.4$ [10% MeOH in DCM]. Light yellow gum. The compound was obtained as a mixture of rotamers as indicated by the NMR spectra. $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 1.14–1.26 (m, 3H), 3.34–3.58 (m, 4H), 4.01–4.18 (m, 4H), 4.34 (s, 2H), 4.53 (s, 2H), 4.74 (s, 2H), 5.53–5.57 (m, 1H), 7.34–7.45 (m, 1H), 11.25 (bs, 1H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 14.0, 48.0 (CH_2), 49.9 (CH_2), 50.7 (CH_2), 58.3 (CH_2), 58.9 (CH_2), 60.5 (CH_2), 61.03(CH_2), 100.6, 146.5, 151.0, 163.9, 167.4, 167.5, 169.1, 169.4. HRMS (ESI $^+$): m/z calcd for $\text{C}_{12}\text{H}_{17}\text{N}_3\text{O}_6\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 322.1015; found: 322.1003.

[[2-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl-acetyl)-(2-hydroxyethyl) amino] acetic acid (8): Compound **7** (0.4 g, 1.34 mmol) was converted to compound **8** (0.22 g, 62%) following the general procedure in Section 3.5. $R_f = 0.2$ [20% MeOH in DCM]. White solid. M.P: 177–179 °C. The compound was obtained as a mixture of rotamers as indicated by the NMR spectra. $^1\text{H-NMR}$ (200 MHz, D_2O): δ 3.54–3.82 (m, 4H), 4.19 (s, 2H), 4.37 (s, 2H), 4.57 (s, 2H), 4.90 (s, 2H), 5.80–5.87 (m, 1H), 7.50–7.56 (m, 1H). $^{13}\text{C-NMR}$ (50 MHz, D_2O): δ 49.2 (CH_2), 50.0 (CH_2), 50.6 (CH_2), 51.0 (CH_2), 59.3 (CH_2), 59.4 (CH_2), 102.2, 148.1, 152.6, 167.2, 170.0, 173.3. HRMS (ESI $^+$): m/z calcd for $\text{C}_{10}\text{H}_{13}\text{N}_3\text{O}_6\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 294.0702; found: 294.0707.

{[2-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl-acetyl)] ethoxycarbonylmethylamino}acetic acid ethyl ester (**9**): Compound **1** (0.52 g, 3.05 mmol) was transformed to compound **9** (0.51 g, 49%) following the general procedure in Section 3.2. $R_f = 0.5$ [70% EtOAc in pet ether]. White solid. M.P: 140–142 °C. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 1.22–1.34 (m, 6H), 4.12–4.31 (m, 8H), 4.61 (s, 2H), 5.73 (d, $J = 8.0$ Hz, 1H), 7.20 (d, $J = 7.8$ Hz, 1H), 9.09 (bs, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ 14.3, 47.7 (CH_2), 49.0 (CH_2), 50.2 (CH_2), 61.8 (CH_2), 62.5 (CH_2), 102.6, 145.2, 151.0, 163.7, 167.6, 168.6. HRMS (ESI^+): m/z calcd for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_7\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 364.1121; found: 364.1109.

{Carboxymethyl-[2-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) acetyl] amino}acetic acid (**10**): Compound **9** (0.42 g, 1.23 mmol) was converted to compound **10** (0.26 g, 74%) following the general procedure in Section 3.5. $R_f = 0.2$ [30% MeOH in DCM]. White solid. M.P: 118–120 °C $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 4.00 (s, 2H), 4.25 (s, 2H), 4.62 (s, 2H), 5.55 (d, $J = 7.2$ Hz, 1H), 7.43 (d, $J = 7.6$ Hz, 1H), 11.28 (s, 1H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 47.7 (CH_2), 48.4 (CH_2), 49.2 (CH_2), 100.7, 146.4, 151.0, 163.8, 167.7, 170.3. HRMS (ESI^+): m/z calcd for $\text{C}_{10}\text{H}_{11}\text{N}_3\text{O}_7\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 308.0495; found: 308.0475.

{[4-[Bis(1,1-dimethylethoxy)carbonyl]amino-2-oxo-2H-pyrimidin-1-yl] acetylamino}acetic acid ethyl ester (**12**): Compound **11** (0.39 g, 1.05 mmol) was converted to compound **12** (0.30 g, 62%) following the general procedure in Section 3.2. $R_f = 0.5$ [60% EtOAc in pet ether]. White solid. M.P: 118–120 °C. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 1.18–1.25 (m, 3H), 1.52 (s, 18H), 3.95 (d, $J = 5.6$ Hz, 2H), 4.12 (q, $J = 7.2$ Hz, 2H), 4.58 (s, 2H), 7.08 (d, $J = 7.2$ Hz, 1H), 7.69–7.76 (m, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ 14.1, 27.7, 41.4 (CH_2), 52.8 (CH_2), 61.4 (CH_2), 85.0, 96.7, 149.0, 149.4, 152.6, 155.5, 162.7, 167.1, 169.4. HRMS (ESI^+): m/z calcd for $\text{C}_{20}\text{H}_{30}\text{N}_4\text{O}_8\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 477.1961; found: 477.1975.

[2-(4-Amino-2-oxo-2H-pyrimidin-1-yl) acetylamino] acetic acid ethyl ester (**13**): Compound **12** (0.28 g, 0.62 mmol) was converted to compound **13** (0.11 g, 72%) following the general procedure in Section 3.4. $R_f = 0.3$ [5% MeOH in DCM]. White solid. M.P: 155–158 °C. $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 1.17 (t, $J = 7.2$ Hz, 3H), 3.86 (d, $J = 5.8$ Hz, 2H), 4.07 (q, $J = 7.2$ Hz, 2H), 4.42 (s, 2H), 5.82 (d, $J = 7.2$ Hz, 1H), 7.65 (d, $J = 7.4$ Hz, 1H), 7.90 (bs, 1H), 8.09 (bs, 1H), 8.61 (t, $J = 5.8$ Hz, 1H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 14.5, 41.2 (CH_2), 50.9 (CH_2), 61.0 (CH_2), 93.8, 148.8, 153.5, 164.4, 168.0, 170.0. HRMS (ESI^+): m/z calcd for $\text{C}_{10}\text{H}_{15}\text{N}_4\text{O}_4$ ($\text{M}+\text{H}$) $^+$: 255.1093; found: 255.1076.

[2-(4-Amino-2-oxo-2H-pyrimidin-1-yl) acetylamino] acetic acid (**14**): Compound **13** (0.09 g, 0.35 mmol) was transformed to compound **14** (0.05 g, 67%) following the general procedure in Section 3.5. $R_f = 0.3$ [20% MeOH in DCM]. Yellowish white solid. M.P: > 200 °C. $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 3.61–3.95 (m, 2H), 4.54 (s, 2H), 6.22 (d, $J = 7.2$ Hz, 1H), 7.99 (d, $J = 7.4$ Hz, 1H), 8.77 (s, 1H), 8.94 (s, 1H), 10.17 (s, 1H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 40.8 (CH_2), 50.4 (CH_2), 93.1, 147.4, 150.6, 160.1, 166.4, 170.8. HRMS (ESI^+): m/z calcd for $\text{C}_8\text{H}_{11}\text{N}_4\text{O}_4$ ($\text{M}+\text{H}$) $^+$: 227.0780; found: 227.0784.

[4-[Bis(1,1-dimethylethoxy)carbonyl]amino-2-oxo-2H-pyrimidin-1-yl]-N,N-bis-[2(tertbutyldimethylsilyloxy)ethyl]acetamide (**15**): Compound **15** (0.55 g, 69%) was obtained from compound **11** (0.43 g, 1.16 mmol) following the general procedure in Section 3.2. $R_f = 0.3$ [25% EtOAc in pet ether]. Colourless gum. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ -0.03 (s, 6H), 0.01 (s, 6H), 0.81 (s, 9H), 0.83 (s, 9H),

1.49 (s, 18H), 3.43 (t, $J = 5.6$ Hz, 2H), 3.64–3.74 (m, 6H), 4.70 (s, 2H), 7.00 (d, $J = 7.4$ Hz, 1H), 7.52 (d, $J = 7.4$ Hz, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ -5.4, 18.2, 18.3, 26.0, 27.7, 49.3 (CH_2), 49.5 (CH_2), 51.1 (CH_2), 61.0 (CH_2), 61.2 (CH_2), 84.8, 96.1, 149.1, 149.6, 155.1, 162.6, 167.1. HRMS (ESI^+): m/z calcd for $\text{C}_{32}\text{H}_{61}\text{N}_4\text{O}_8\text{Si}_2$ ($\text{M}+\text{H}$) $^+$: 685.4028; found: 685.4038.

2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-N,N-bis-(2-hydroxyethyl) acetamide (16): Compound **15** (0.48 g, 0.70 mmol) was transformed to compound **16** (0.13 g, 71%) following the general procedure in Section 3.4. $R_f = 0.3$ [15% MeOH in DCM]. White solid. M.P: 150 °C (decomposed). $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 2.99–3.04 (m, 1H), 3.34–3.68 (m, 8H), 4.65 (s, 2H), 5.78 (d, $J = 7.2$ Hz, 1H), 7.51 (d, $J = 7.2$ Hz, 1H), 7.75 (bs, 2H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 48.8 (CH_2), 49.3 (CH_2), 49.9 (CH_2), 58.7 (CH_2), 59.0 (CH_2), 93.2, 148.1, 154.4, 164.8, 167.3. HRMS (ESI^+): m/z calcd for $\text{C}_{10}\text{H}_{17}\text{N}_4\text{O}_4$ ($\text{M}+\text{H}$) $^+$: 257.1250; found: 257.1255.

{[4-[Bis(1,1-dimethylethoxy)carbonyl]amino-2-oxo-2H-pyrimidin-1-yl-acetyl]-[2-(tert-butyl)dimethylsilyloxy] ethyl} acetic acid ethyl ester (17): Compound **11** (0.46 g, 1.24 mmol) was converted to compound **17** (0.52 g, 69%) following the general procedure in Section 3.2. $R_f = 0.4$ [40% EtOAc in pet ether]. Colorless gum. The compound was obtained as a mixture of rotamers as indicated by the NMR spectra. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ -0.03–0.01 (m, 6H), 0.81 (s, 9H), 0.83 (s, 9H), 1.15–1.27 (m, 3H), 1.49 (s, 18H), 3.33–3.80 (m, 4H), 4.05–4.18 (m, 4H), 4.40 (s, 2H), 4.49 (s, 2H), 4.75 (s, 2H), 6.97–7.03 (m, 1H), 7.54–7.62 (m, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ -5.4, 14.2, 18.2, 25.9, 27.7, 49.0 (CH_2), 49.3 (CH_2), 51.1 (CH_2), 51.2 (CH_2), 61.2 (CH_2), 61.6 (CH_2), 61.8 (CH_2), 62.0 (CH_2), 84.8, 96.2, 149.0, 149.1, 149.5, 155.0, 162.7, 162.8, 167.4, 167.5, 168.8, 169.7. HRMS (ESI^+): m/z calcd for $\text{C}_{28}\text{H}_{49}\text{N}_4\text{O}_9\text{Si}$ ($\text{M}+\text{H}$) $^+$: 613.3269; found: 613.3278.

[[2-(4-Amino-2-oxo-2H-pyrimidin-1-yl) acetyl]-(2-hydroxyethyl) amino] acetic acid (18): Compound **17** (0.40 g, 0.65 mmol) was hydrolyzed to corresponding acid following the general procedure in Section 3.5. The *crude* residue obtained was subjected to TFA treatment as mentioned in the general procedure in Section 3.4, and purified by column chromatography over silica gel to obtain **18** (0.10 g, 58%). $R_f = 0.2$ [30% MeOH in DCM]. White solid. M.P: 184–188 °C. The compound was obtained as a mixture of rotamers, as indicated by the NMR spectra. $^1\text{H-NMR}$ (200 MHz, $\text{DMSO-}d_6$): δ 3.35–3.59 (m, 4H), 4.01 (s, 2H), 4.24 (s, 2H), 4.54 (s, 2H) 4.75 (s, 2H), 5.84 (d, $J = 7.0$ Hz, 1H), 7.55 (d, $J = 7.0$ Hz, 1H), 7.97 (bs, 2H). $^{13}\text{C-NMR}$ (50 MHz, $\text{DMSO-}d_6$): δ 47.9 (CH_2), 49.1 (CH_2), 49.9 (CH_2), 58.9 (CH_2), 93.4, 148.6, 152.8, 163.6, 167.6, 170.7, 171.1. HRMS (ESI^+): m/z calcd for $\text{C}_{10}\text{H}_{15}\text{N}_4\text{O}_5$ ($\text{M}+\text{H}$) $^+$: 271.1042; found: 271.1039.

{[4-[Bis(1,1-dimethylethoxy)carbonyl]amino-2-oxo-2H-pyrimidin-2-yl-acetyl] ethoxycarbonylmethylamino} acetic acid ethyl ester (19): Compound **19** (0.29 g, 54%) was generated from compound **11** (0.37 g, 1.00 mmol) following the general procedure in Section 3.2. $R_f = 0.4$ [50% EtOAc in pet ether]. Colorless gum. $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 1.17–1.30 (m, 6H), 1.51 (s, 18H), 4.07–4.25 (m, 6H), 4.32 (s, 2H), 4.67 (s, 2H), 7.05 (d, $J = 7.4$ Hz, 1H), 7.62 (d, $J = 7.4$ Hz, 1H). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ 14.2, 27.8, 49.1 (CH_2), 49.4 (CH_2), 50.5 (CH_2), 61.6 (CH_2), 62.1 (CH_2), 85.0, 96.5, 149.0, 149.5, 155.1, 162.8, 167.9, 168.7, 168.9. HRMS (ESI^+): m/z calcd for $\text{C}_{24}\text{H}_{37}\text{N}_4\text{O}_{10}$ ($\text{M}+\text{H}$) $^+$: 541.2510; found: 541.2516.

{[2-(4-Amino-2-oxo-2H-pyrimidin-1-yl) acetyl] ethoxycarbonylmethylamino}acetic acid ethyl ester (**20**): Compound **19** (0.27 g, 0.50 mmol) was converted to compound **20** (0.09 g, 56%) following the general procedure in Section 3.4. $R_f = 0.3$ [3% MeOH in DCM]. White solid. M.P: 152–154 °C. $^1\text{H-NMR}$ (200 MHz, DMSO- d_6): δ 1.14–1.27 (m, 6H), 4.00–4.22 (m, 6H), 4.39 (s, 2H), 4.80 (s, 2H), 6.10 (d, $J = 7.6$ Hz, 1H), 7.81 (d, $J = 7.6$ Hz, 1H), 9.52 (bs, 1H), 9.67 (bs, 1H). $^{13}\text{C-NMR}$ (50 MHz, DMSO- d_6): δ 14.0, 48.5 (CH₂), 49.1 (CH₂), 60.6 (CH₂), 61.1 (CH₂), 93.5, 148.2, 150.2, 160.6, 167.3, 168.5, 168.8. HRMS (ESI⁺): m/z calcd for C₁₄H₂₁N₄O₆ (M+H)⁺: 341.1461; found: 341.1452.

{[2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-acetyl] carboxymethylamino}acetic acid (**21**): Compound **20** (0.07 g, 0.20 mmol) was transformed to compound **21** (0.04 g, 66%) following the general procedure in Section 3.5. $R_f = 0.15$ [40% MeOH in DCM]. Eluent: 30%–50% MeOH in DCM. White solid. M.P: 190–193 °C. $^1\text{H-NMR}$ (200 MHz, D₂O): δ 4.23 (s, 2H), 4.39 (s, 2H), 4.89 (s, 2H), 6.24 (d, $J = 7.4$ Hz, 1H), 7.79 (d, $J = 7.8$ Hz, 1H). $^{13}\text{C-NMR}$ (50 MHz, DMSO- d_6): δ 48.8 (CH₂), 49.3 (CH₂), 49.9 (CH₂), 93.4, 148.4, 152.2, 163.5, 167.8, 170.4, 170.7. HRMS (ESI⁺): m/z calcd for C₁₀H₁₃N₄O₆ (M+H)⁺: 285.0835; found: 285.0852.

3.6. Comparative Agarose Gel-Based Assay

Inhibition of RNase A was assayed qualitatively by the degradation of RNA in an agarose gel. In this method, 20 μL of RNase A (1 μM) was mixed with 20 μL (0.5 mM) of compounds **U-ol-ol** (**5**), **C-ol-ol** (**16**), **U-acid** (**3**), **C-acid** (**14**), **U-ol-acid** (**8**), **C-ol-acid** (**18**), **U-di-acid** (**10**), and **C-di-acid** (**21**) separately to a final volume of 50 μL and the resulting solutions incubated for 3 h. Twenty-microliter aliquots of the incubated mixtures were then mixed with 20 μL of RNA solution (10.0 mg/mL RNA, freshly dissolved in RNase free water) and incubated for another 30 min. Then 10 μL of sample buffer (containing 10% glycerol and 0.025% bromophenol blue) were added to this mixture and 15 μL from each solution were extracted and loaded onto a 1.1% agarose gel. The gel was run using a 0.04-M Tris-Acetic acid-EDTA (TAE) buffer (pH 8.0). The residual RNA was visualized by ethidium bromide staining under UV light.

3.7. Inhibition Kinetics with RNase A

A quantitative account of RNase A inhibition by the individual inhibitors was obtained by a UV spectroscopic method described by Anderson and co-workers [22]. The assay was performed in a 0.1-M Mes-NaOH buffer, pH 6.0 containing 0.1 M NaCl using 2',3'-cCMP as the substrate. The inhibition constants were calculated from initial velocity data using a Lineweaver–Burk plot. The slopes from the Lineweaver–Burk double reciprocal plot were plotted against the corresponding inhibitor concentrations to get inhibition constants (K_i).

3.8. Circular Dichroism Measurements

Circular Dichroism (CD) was performed in order to monitor the changes in the secondary structure of the enzyme as a result of interaction with the inhibitors. In this method, 200 μL of RNase A (30 μM) were mixed separately with 200 μL of **U-di-acid** (**10**) (30 μM) and **C-di-acid** (**21**) (30 μM) and incubated for 3 h. From the resulting solutions, an aliquot of 300 μL was used for CD measurements,

taking a 1 mm path length quartz cell. The spectra were recorded in the range of 190–240 nm with a scan rate of 50 nm/min. Three scans were accumulated for each spectrum. The secondary structure was determined using an online server, DICHROWEB [46].

3.9. Fluorescence Spectroscopy

Fluorescence quenching study was performed to garner an idea of the binding affinities of **U-di-acid (10)** and **C-di-acid (21)** towards RNase A. The emission spectra were recorded from 290 to 400 nm with excitation at 275 nm [47] using a 5 nm slit width. The interaction between the ligands and RNase A was investigated by titration of 3 mL solution of RNase A with successive addition of the respective ligands (0–15 μM) in a 20-mM phosphate buffer of pH 7.0. Binding constants (K_b) were calculated using double-logarithm plot [48].

3.10. FlexX Docking

The crystal structure of RNase A (PDB entry 1FS3) was downloaded from the Protein Data Bank [49]. The 3D structures of the inhibitors were generated in *Sybyl6.92* (Tripos Inc., St. Louis, MO, USA). Minimum energy conformations were obtained with the help of the MMFF94 force field using MMFF94 charges with a gradient of 0.005 kcal/mole by 1000 iterations with all other default parameters. The ligands were docked with the protein using *FlexX* software. The ranking of the generated solutions was performed using a scoring function that estimates the free binding energy (ΔG) of the protein-ligand complex considering various types of molecular interactions [50]. Docked conformations were visualized using *PyMol* [51].

3.11. Accessible Surface Area Calculations

Accessible surface area of uncomplexed RNase A and its docked complexes were calculated using the program *NACCESS*. The structures obtained from the *FlexX* analysis were used for the calculation. The change in ASA for a particular residue X was calculated using: $\Delta ASA^X = ASA^X_{RNase A} - ASA^X_{RNase A + inhibitor}$.

4. Conclusions

Strategically designed carboxylated acyclonucleosides have been established as moderate RNase A inhibitors. The experimental outcome points towards the possible contribution of a sugar ring in RNase A inhibition. Cytosine analogues have been proven to have better inhibitory properties than the corresponding uracil derivatives. **C-di-acid (21)** emerged as the most potent inhibitor of the series, having an inhibition constant (K_i) value of 235 μM . It was observed that an increment in the number of carboxylic acid groups resulted in better inhibitory properties. However, the absence of the rigid ribose ring in the molecules significantly affects the inhibition properties of the synthetic nucleosides. These findings should act as a guideline for future design of inhibitors for RNase A and other members of the ribonuclease superfamily.

Supplementary Materials

Supplementary materials can be accessed at: <http://www.mdpi.com/1420-3049/20/04/5924/s1>.

Acknowledgments

The authors thank the Department of Biotechnology, Ministry of Science and Technology, New Delhi for funding (project no. SB/S1/OC-30/2014). Kaustav Chakraborty thanks D. Tripathy and S. Ghosh for their help in some of the experiments and the Council for Scientific and Industrial Research, New Delhi for a fellowship.

Author Contributions

S.D.G and T.P conceived the idea and designed the study. K.C performed the synthetic and biological experiments, and analyzed the data. K.C, S.D.G, and T.P wrote the manuscript together. All authors read and approved the final version of the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. D'Alessio, G. The superfamily of vertebrate-secreted ribonucleases. In *Ribonucleases*; Nicholson, A.W., Ed.; Springer: Heidelberg, Germany, 2011; pp. 1–34.
2. Loverix, S.; Steyaert, J. Ribonucleases: from prototypes to therapeutic targets. *Curr. Med. Chem.* **2003**, *10*, 779–785.
3. Viola, M.; Libra, M.; Callari, D.; Sinatra, F.; Spada, D.; Noto, D.; Emmanuele, G.; Romano, F.; Averna, M.; Pezzino, F.M.; *et al.* Bovine seminal ribonuclease is cytotoxic for both malignant and normal telomerase-positive cells. *Int. J. Oncol.* **2005**, *27*, 1071–1077.
4. Zrinski, R.T.; Dodig, S. Eosinophil cationic protein-current concept and controversies. *Biochem. Med.* **2011**, *21*, 111–121.
5. Li, S.; Ibaragi, S.; Hu, G. Angiogenin as a molecular target for the treatment of prostate cancer. *Curr. Cancer Ther. Rev.* **2011**, *7*, 83–90.
6. Fang, E.F.; Ng, T.B. Ribonucleases of different origins with a wide spectrum of medicinal applications. *Biochim. Biophys. Acta* **2011**, *1815*, 65–74.
7. Leland, P.A.; Schultz, L.W.; Kim, B.; Raines, R.T. Ribonuclease A variants with potent cytotoxic activity. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 10407–10412.
8. Leland, P.A.; Staniszewski, K.E.; Park, C.; Kelemen, B.R.; Raines, R.T. The ribonucleolytic activity of angiogenin. *Biochemistry* **2002**, *41*, 1343–1350.
9. Raines, R.T. Ribonuclease A. *Chem. Rev.* **1998**, *98*, 1045–1065.
10. Marshall, G.; Feng, J.A.; Kuster, D.J. Back to the future: ribonuclease A. *Biopolymers* **2007**, *90*, 259–277.
11. Shapiro, R.; Weremowicz, S.; Riordan, J.F.; Vallee, B.L. Ribonucleolytic activity of angiogenin: Essential histidine, lysine, and arginine residues. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 8783–8787.
12. Hamann, K.J.; Barker, R.L.; Loegering, D.A.; Pease, L.R.; Gleich, G.L. Sequence of human eosinophil-derived neurotoxin cDNA: Identity of deduced amino acid sequence with human nonsecretory ribonucleases. *Gene* **1989**, *83*, 161–167.

13. Gagné, D.; Charest, L.; Morin, S.; Kovrigin, E.L.; Doucet, N. Conservation of flexible residue clusters among structural and functional enzyme homologues. *J. Biol. Chem.* **2012**, *287*, 44289–44300.
14. Maiti, T.K.; De, S.; Dasgupta, S.; Pathak, T. 3'-N-Alkylamino-3'-deoxy-*ara*-uridines: A new class of potential inhibitors of ribonuclease A and angiogenin. *Bioorg. Med. Chem.* **2006**, *14*, 1221–1228.
15. Leonidas, D.D.; Maiti, T.K.; Samanta, A.; Dasgupta, S.; Pathak, T.; Zographos, S.E.; Oikonomakos, N.G. The binding of 3'-N-piperidine-4-carboxyl-3'-deoxy-*ara*-uridine to ribonuclease A in the crystal. *Bioorg. Med. Chem.* **2006**, *14*, 6055–6066.
16. Debnath, J.; Dasgupta, S.; Pathak, T. Inhibition of ribonuclease A by nucleoside-dibasic acid conjugates. *Bioorg. Med. Chem.* **2009**, *17*, 6491–6496.
17. Debnath, J.; Dasgupta, S.; Pathak, T. Comparative inhibitory activity of 3'- and 5'-functionalized nucleosides on ribonuclease A. *Bioorg. Med. Chem.* **2010**, *18*, 8257–8263.
18. Samanta, A.; Dasgupta, S.; Pathak, T. 5'-modified pyrimidine nucleosides as inhibitors of ribonuclease A. *Bioorg. Med. Chem.* **2009**, *17*, 6491–6496.
19. Datta, D.; Samanta, A.; Dasgupta, S.; Pathak, T. 3'-Oxo-, amino-, thio-, and sulfone-acetic acid modified thymidines: Effect of increased acidity on ribonuclease A inhibition. *Bioorg. Med. Chem.* **2013**, *21*, 4634–4645.
20. Datta, D.; Samanta, A.; Dasgupta, S.; Pathak, T. Synthesis of 5'-carboxymethylsulfonyl-5'-deoxyribonucleosides under mild hydrolytic conditions: A new class of acidic nucleosides as inhibitors of ribonuclease A. *RSC Adv.* **2014**, *4*, 2214–2218.
21. Datta, D.; Dasgupta, S.; Pathak, T. Ribonuclease A inhibition by carboxymethylsulfonyl-modified xylo- and arabinopyrimidines. *ChemMedChem* **2014**, *9*, 2138–2149.
22. Anderson, D.G.; Hammes, G.G.; Walz, F.G. Binding of phosphate ligands to ribonuclease A. *Biochemistry* **1968**, *7*, 1637–1645.
23. Walz, F.G. Kinetic and equilibrium studies on the interaction of ribonuclease A and 2'-deoxyuridine 3'-phosphate. *Biochemistry* **1971**, *10*, 2156–2162.
24. Russo, N.; Shapiro, R.; Vallee, B.L. 5'-Diphosphoadenosine-3'-phosphate is a potent inhibitor of bovine pancreatic ribonuclease A. *Biochem. Biophys. Res. Commun.* **1997**, *231*, 671–674.
25. Leonidas, D.D.; Shapiro, R.; Irons, L.I.; Russo, N.; Acharya, K.R. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 Å resolution. *Biochemistry* **1997**, *36*, 5578–5588.
26. Leonidas, D.D.; Shapiro, R.; Irons, L.I.; Russo, N.; Acharya, K.R. Towards rational design of ribonuclease inhibitors: High resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor. *Biochemistry* **1999**, *38*, 10287–10297.
27. Russo, N.; Shapiro, R. Potent inhibition of mammalian ribonucleases by 3',5'-pyrophosphate-linked nucleotides. *J. Biol. Chem.* **1999**, *274*, 14902–14908.
28. Leonidas, D.D.; Chavali, G.B.; Oikonomakos, N.G.; Chrysina, E.D.; Kosmopoulou, M.N.; Vlassi, M.; Frankling, C.; Acharya, K.R. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors. *Protein Sci.* **2003**, *12*, 2559–2574.
29. Kumar, K.; Jenkins, J.L.; Jardine, A.M.; Shapiro, R. Inhibition of mammalian ribonucleases by endogenous adenosine dinucleotides. *Biochem. Biophys. Res. Commun.* **2003**, *300*, 81–86.

30. Jenkins, C.L.; Thiyagarajan, N.; Sweeney, R.Y.; Guy, M.P.; Kelemen, B.R.; Acharya, K.R.; Raines, R.T. Binding of non-natural 3'-nucleotides to ribonuclease A. *FEBS J.* **2005**, *272*, 744–755.
31. Hatzopoulos, G.N.; Leonidas, D.D.; Kardakaris, R.; Kobe, J. Oikonomakos, N.G. The binding of IMP to ribonuclease A. *FEBS J.* **2005**, *272*, 3988–4001.
32. Yakovlev, G.I.; Mitkevich, V.A.; Makarov, A.A. Ribonuclease inhibitors. *Mol. Biol.* **2006**, *40*, 867–874.
33. Nogués, M.V.; Vilanova, M.; Cuchillo, C.M. Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. *Biochim. Biophys. Acta* **1995**, *1253*, 16–24.
34. Findlay, D.; Herries, D.G.; Mathias, A.P.; Rabin, B.R.; Ross, C.A. The active site and mechanism of action of bovine pancreatic ribonuclease. *Nature* **1961**, *190*, 781–784.
35. Cuchillo, C.M.; Nogués, M.V.; Raines, R.T. Bovine pancreatic ribonuclease: Fifty years of the first enzymatic reaction mechanism. *Biochemistry* **2011**, *50*, 7835–7841.
36. Silverman, R.B. *The Organic Chemistry of Drug Design and Drug Action*, 2nd ed.; Elsevier: San Diego, CA, USA, 2004; p. 126.
37. Liu, X.; Chen, R. Synthesis of novel phosphonotripeptides containing uracil or thymine group. *Phosphorus Sulfur Silicon Relat. Elem.* **2001**, *176*, 19–28.
38. Rezazgui, O.; Boëns, B.; Teste, K.; Vergaud, J.; Trouillas, P.; Zerrouki, R. One-pot and catalyst-free amidation of ester: A matter of non-bonding interactions. *Tetrahedron Lett.* **2011**, *52*, 6796–6799.
39. Porcheddu, A.; Giacomelli, G.; Piredda, I.; Carta, M.; Nieddu, G. A practical and efficient approach to PNA monomers compatible with Fmoc-mediated solid-phase synthesis protocols. *Eur. J. Org. Chem.* **2008**, *34*, 5786–5797.
40. Gaudreau, S.; Novetta-dellen, A.; Neault, J.F.; Diamantoglou, S.; Tajmir-riahi, H.A. 3'-azido-3'-deoxythymidine binding to ribonuclease A: Model for drug-protein interaction. *Biopolymers* **2003**, *72*, 435–441.
41. Ghosh, K.S.; Maiti, T.K.; Mandal, A.; Dasgupta, S. Copper complexes of (-)-epicatechin gallate and (-)-epigallocatechin gallate act as inhibitors of ribonuclease A. *FEBS Lett.* **2006**, *580*, 4703–4708.
42. Ghosh, K.S.; Debnath, J.; Dutta, P.; Sahoo, B.K.; Dasgupta, S. Exploring the potential of 3'-O-carboxy esters of thymidine as inhibitors of ribonuclease A and angiogenin. *Bioorg. Med. Chem.* **2008**, *16*, 2819–2828.
43. Dutta, S.; Basak, A.; Dasgupta, S. Synthesis and ribonuclease A inhibition activity of resorcinol and phloroglucinol derivatives of catechin and epicatechin: Importance of hydroxyl groups. *Bioorg. Med. Chem.* **2010**, *18*, 6538–6546.
44. Tripathy, D.R.; Roy, A.S.; Dasgupta, S. Complex formation of rutin and quercetin with copper alters the mode of inhibition of ribonuclease A. *FEBS Lett.* **2011**, *585*, 3270–3276.
45. Sela, M.; Anfinsen, C.B. Some spectrophotometric and polarimetric experiments with ribonucleases. *Biochim. Biophys. Acta* **1957**, *24*, 229–235.
46. Whitmore, L.; Wallace, B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Res.* **2004**, *32*, 668–673.
47. Garcia-Borron, J.C.; Escribano, J.; Jimenez, M.; Iborra, J.L. Quantitative determination of tryptophanyl and tyrosyl residues of proteins by second-derivative fluorescence spectroscopy. *Anal. Biochem.* **1982**, *125*, 277–285.

48. Jiang, M.; Xie, M.X.; Zheng, D.; Liu, Y.; Li, X.Y.; Cheng, X. Spectroscopic studies on the interaction of cinnamic acid and its hydroxyl derivatives with human serum albumin. *J. Mol. Struct.* **2004**, *692*, 71–80.
49. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.
50. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. *J. Mol. Biol.* **1996**, *261*, 470–489.
51. DeLano, W.L. *The PyMOL Molecular Graphics System*; DeLano Scientific: San Carlos, CA, USA, 2004. Available online: <http://pymol.sourceforge.net/>.

Sample Availability: Samples are not available from authors.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).